- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03865550
Post-op Ketamine Study
March 5, 2019 updated by: Rothman Institute Orthopaedics
Evaluation of Post Operative Pain Following Primary Total Knee Arthroplasty (TKA) With Intraoperative Subanesthetic Ketamine Administration and Spinal Anesthesia
The purpose of this study is to establish the effect of sub-anesthetic dosing of ketamine with spinal anesthesia during total knee arthroplasty on post-operative pain and narcotic consumption.
We hypothesize that sub-anesthetic ketamine will decrease post-operative pain and narcotic consumption and may secondarily lead to shorter lengths of stay, faster rehabilitation, improved postoperative outcomes and patient satisfaction.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
75
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Rothman Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
- 18 - 85 years of age
- ASA I - IV
- Undergoing primary unilateral elective total knee arthroplasty with spinal anesthesia
Exclusion Criteria:
- BMI over 40*
- Contraindication or allergy to opioid pain medication or ketamine*
- Daily opioid use for pain control before surgery in excess of systemic morphine equivalent to 10 mg*
- Ejection fraction (EF) less than 30%
- Creatinine clearance less than 30 mL/min*
- History of chronic liver failure
- Desire for nerve block or general anesthesia
- Any neurologic or psychiatric disorder (including bipolar disorder, post traumatic stress disorder, schizophrenia)
- Prior surgery on ipsilateral knee within the last 6 months
- Alcohol abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Placebo
|
|
ACTIVE_COMPARATOR: Ketamine
|
Active comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain as reported on Visual Analog Scale
Time Frame: Up to 6 weeks post-operatively
|
VAS pain reported 0-100mm
|
Up to 6 weeks post-operatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 28, 2016
Primary Completion (ACTUAL)
April 27, 2018
Study Completion (ANTICIPATED)
April 27, 2019
Study Registration Dates
First Submitted
March 5, 2019
First Submitted That Met QC Criteria
March 5, 2019
First Posted (ACTUAL)
March 7, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 7, 2019
Last Update Submitted That Met QC Criteria
March 5, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
- 2016Levicoff
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.